TAK-503

· Shire

Drug timelines are a Plus or Pro feature.

1 regulatory and trial event tracked for TAK-503, covering 2026-04-13 to 2026-04-13. Get the full timeline:

Most recent: Clinical Trial Update: A Study of TAK-503 in Children and Teenagers With Attention Deficit Hyperactivity Disorder (ADHD) [Phase 4]